文献速递消化道肿瘤与早癌消化内镜

DNA甲基化标志物对幽门螺杆菌根除后原发性胃癌的精准风险分层:一项多中心前瞻性研究

Precision risk stratification of primary gastric cancer after eradication of H. pylori by a DNA methylation marker: a multicentre prospective study.
PubMed 文献 · Gut · 2025-08-07

该多中心前瞻性研究在幽门螺杆菌根除后伴开放性萎缩的健康人群中检测RIMS1基因DNA甲基化水平,随访1624人、中位4.05年,27人发生原发性胃癌;最高四分位组发病率972.8/10万人年高于最低四分位组127.1,年龄性别调整HR 5.7(95%CI 1.3-25.5)。

要点

  • 幽门螺杆菌根除后伴开放性萎缩人群可用RIMS1甲基化水平进行胃癌风险分层。
  • 最高四分位组胃癌发病率972.8/10万人年,最低四分位组为127.1。
  • 作者认为超高危个体需要比现行推荐更频繁的胃癌筛查。

核心结论

  • DNA甲基化标志物可在幽门螺杆菌根除后的健康人群中进行风险分层,即使这些人群临床上均属高风险。
  • 超高危个体将需要比现行推荐更频繁的胃癌筛查。

研究设计与样本

  • 多中心前瞻性研究,前瞻性纳入幽门螺杆菌根除后伴开放性萎缩的健康人群。
  • 在胃窦和胃体活检标本中检测标志基因RIMS1的DNA甲基化水平。
  • 主要终点为按甲基化水平四分位分组的胃癌发病率。
  • 1624名参与者至少完成一次内镜随访,中位随访4.05年,27人发生原发性胃癌。
  • 试验注册号:UMIN-CTR000016894。

主要发现

  • RIMS1甲基化水平最高四分位组胃癌发病率972.8/10万人年,高于最低四分位组的127.1/10万人年。
  • Cox回归分析显示单变量HR为7.7(95%CI 1.8-33.7),年龄和性别调整后HR为5.7(95%CI 1.3-25.5)。
  • 作为次要目标,基于需筛查人数1000,获得识别超高危人群的甲基化临界值25.7%(95%CI 1.7-7.7)。

关键数值与推荐

  • RIMS1甲基化水平最高四分位组胃癌发病率972.8/10万人年,最低四分位组为127.1/10万人年。
  • 单变量HR 7.7(95%CI 1.8-33.7),年龄和性别调整后HR 5.7(95%CI 1.3-25.5)。
  • 识别超高危人群的甲基化临界值为25.7%(95%CI 1.7-7.7),基于需筛查人数1000。

临床怎么用

  • 作者认为,DNA甲基化标志物可用于幽门螺杆菌根除后健康人群的风险分层。
  • 作者认为,超高危个体将需要比现行推荐更频繁的胃癌筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precision cancer risk stratification for gastric cancer is urgently needed for the growing number of healthy people after Helicobacter pylori eradication. The epimutation burden in non-malignant tissues has been associated with cancer risk in multiple cross-sectional studies. OBJECTIVE: To confirm the clinical usefulness of a DNA methylation marker for epimutation burden, and to identify a cut-off methylation level for a super-high-risk population. DESIGN: Healthy people after H. pylori eradication with open-type atrophy were prospectively recruited. DNA methylation levels of a marker gene, RIMS1, were measured in biopsy specimens from gastric antrum and body. The primary endpoint was the incidence rate of gastric cancer in quartiles of the methylation levels. RESULTS: 1624 participants had at least one endoscopic follow-up with a median follow-up of 4.05 years, and a primary gastric cancer developed in 27 participants. The highest quartile of RIMS1 methylation levels had a higher incidence rate (972.8 per 100 000 person-years) than the lowest quartile (127.1). Cox regression analysis revealed a univariate HR of 7.7 (95% CI 1.8-33.7) and an age- and sex-adjusted HR of 5.7 (95% CI 1.3-25.5). As a secondary objective, a cut-off methylation level of 25.7% (95% CI 1.7-7.7) was obtained to identify a population with a super-high risk based on the number needed to screen of 1000. CONCLUSION: A DNA methylation marker can risk-stratify healthy people after H. pylori eradication even though all of them have clinically high risk. Individuals with super-high risk will need more frequent gastric cancer screening than currently recommended. TRIAL REGISTRATION NUMBER: UMIN-CTR000016894.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yamada H, Abe S, Charvat H, et al. Precision risk stratification of primary gastric cancer after eradication of H. pylori by a DNA methylation marker: a multicentre prospective study. Gut. 2025. PMID: 40240063. doi:10.1136/gutjnl-2025-335039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。